Izotropic Launches Podcast Episode #1: Beyond the Mammogram: Rethinking the Future of Breast Imaging

Rhea-AI Summary

Izotropic Corporation (OTCQB: IZOZF) has launched a new podcast series focused on breast imaging innovation, with its first episode titled "Beyond the Mammogram: Rethinking the Future of Breast Imaging." The podcast, available in seven languages including English, aims to educate global audiences about advancements in breast cancer detection technology.

The premiere episode discusses the limitations of current breast imaging methods, particularly for the approximately 50% of women with dense breast tissue. With breast cancer projected to affect over 315,000 women in the U.S. in 2025, the podcast highlights the need for improved detection technologies, including Izotropic's flagship product IzoView, a dedicated Breast CT Imaging System.

Positive

• Multi-language podcast launch (7 languages) expands global market reach and awareness
• Strategic timing with breast cancer affecting 315,000 women in U.S. in 2025
• Educational initiative supports commercialization of IzoView Breast CT Imaging System

Negative

• Product still pending regulatory approval
• Competing with established imaging technologies in a crowded market

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of its new podcast series. The first episode Beyond the Mammogram: Rethinking the Future of Breast Imaging is now available in English, Arabic, Chinese, French, German, Italian and Spanish.

The podcast marks a new initiative in the Company’s ongoing mission to inform and engage broader global audiences about innovations in breast imaging. Through accessible and engaging conversations, the series will explore the evolving landscape of breast cancer detection, highlighting clinical challenges, market dynamics, and the technologies poised to reshape the industry and patient care.

In the premiere episode, listeners will hear a compelling discussion about the limitations of current imaging tools, including mammography, digital breast tomosynthesis, ultrasound, and MRI, particularly in screening women with dense breast tissue, who represent approximately 50% of the population. With breast cancer projected to affect over 315,000 women in the U.S. in 2025, the episode highlights the urgent need for imaging technologies that offer earlier, more accurate detection and a better patient experience.

The podcast draws on insights from recent industry data, regulatory updates, and the Company’s own developments, offering a fresh perspective on Izotropic’s mission and its flagship product, IzoView, a first-of-its-kind dedicated Breast CT Imaging System.

This new communications platform repackages publicly disclosed information into a conversational format that’s both educational and accessible to patients, healthcare professionals, and stakeholders across the breast health ecosystem. The Company intends to use the podcast to support broader awareness-building efforts as it advances IzoView toward regulatory approval and market launch.

Episode 1 of the podcast is available now on the Company’s YouTube channel. Subscribe to stay informed about future episodes covering breast imaging trends, patient advocacy, and medical imaging innovation.

Podcast Sources Cited:

1. Izotropic Corporation (July 29, 2025) Izotropic’s IzoView Breast CT Device Stands Distinct vs Existing Breast Imaging Technologies. [Press Release]. https://www.investorwire.com/newsarticle/?qmstory=5535744170701878
   
   
2. Izotropic Corporation (August 5, 2025) Izotropic’s IzoView Positioned to Capitalize on Key Global Breast Imaging Market Drivers [Press Release]. https://www.investorwire.com/newsarticle/?qmstory=8776674626207663

3. Murphy, H. (2025, July 10). Over 100 AI-enabled radiology algorithms added to FDA's list of approvals. Health Imaging. Retrieved July 14, 2025, from https://healthimaging.com/topics/healthcare-management/healthcare-policy/over-100-ai-enabled-radiology-algorithms-added-fdas-list-approvals?utm_source=newsletter&utm_medium=hi_news_alert
   
   
4. Carey, L. (2025, July 14). Radiology drives July FDA AI-enabled medical device update. Aunitminnie.com. Retrieved July 14, 2025, from https://www.auntminnie.com/imaging-informatics/artificial-intelligence/article/15750598/radiology-drives-july-fda-aienabled-medical-device-update?utm_campaign=2025-07-19&utm_source=AuntMinnie-Letter+From+The+Editor&since=1752987600000&braze_int_id=64e760629860e800019ad93c&braze_ext_id=6430325219ef38833c537806&utm_medium=email
   
   
5. Allegretto, A. (2025, July 14). Rural women more prone to advanced-stage breast cancer. Aunitminnie.com. Retrieved July 14, 2025, from https://www.auntminnie.com/clinical-news/womens-imaging/article/15750577/rural-women-more-prone-to-advancedstage-breast-cancer?utm_campaign=2025-07-15&utm_source=AuntMinnie-Letter+From+The+Editor&since=1752642000000&braze_int_id=64e760629860e800019ad93c&braze_ext_id=6430325219ef38833c537806&utm_medium=email
   
   
6. Murphy, H. (2025, July 16). Reimbursement for contrast-enhanced mammography is on the rise. Health Imaging. Retrieved July 16, 2025, from https://healthimaging.com/topics/medical-imaging/womens-imaging/reimbursement-contrast-enhanced-mammography-rise?utm_source=newsletter&utm_medium=hi_news
   
   
7. Murphy, H. (2025, July 15). GPT-4o's 'all or nothing' accuracy continues to hinder its radiologic capabilities. Health Imaging. Retrieved July 16, 2025, from https://healthimaging.com/topics/artificial-intelligence/gpt-4os-all-or-nothing-accuracy-continues-hinder-its-radiologic-capabilities?utm_source=newsletter&utm_medium=hi_weekly

About Izotropic:

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.

Disclaimer & Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Podcast episodes are generated with the assistance of Google AI. Content was produced using generative tools and may contain machine-generated elements. Listeners are encouraged to verify all information through official sources.

Contacts:

Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email:  bthast@izocorp.com

James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2

General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com

Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

FAQ

What is the main focus of Izotropic's (IZOZF) new podcast series?

The podcast focuses on innovations in breast imaging, discussing limitations of current imaging tools and the future of breast cancer detection technology, particularly highlighting their IzoView Breast CT Imaging System.

In how many languages is Izotropic's (IZOZF) first podcast episode available?

The first episode is available in seven languages: English, Arabic, Chinese, French, German, Italian, and Spanish.

What percentage of women have dense breast tissue according to Izotropic's podcast?

According to the podcast, approximately 50% of women have dense breast tissue, which presents challenges for current imaging methods.

How many women are projected to be affected by breast cancer in the U.S. in 2025?

The podcast states that over 315,000 women in the U.S. are projected to be affected by breast cancer in 2025.

Where can investors access Izotropic's (IZOZF) new podcast episode?

The first episode is available on Izotropic Corporation's YouTube channel.